Zai Lab Agrees To Sell $250 Million Of Shares At $22.04 To Fund Its Lung Cancer Drug

A TCGX-led group, joined by RA Capital, RTW and Wellington, would buy 11,340,000 ADSs in a private placement expected to close October 27.

Share
Zai Lab Agrees To Sell $250 Million Of Shares At $22.04 To Fund Its Lung Cancer Drug

Zai Lab, the China-and-US biopharma that sells licensed cancer and immune drugs, agreed Thursday to sell 11,340,000 American depositary shares at $22.04 each, for expected gross proceeds of about $250 million. The private placement is led by TCGX, and the company says the money is mainly for its DLL3-targeting cancer drug, zoci.

Who is buying, and at what price

Each ADS represents ten ordinary shares. The $250 million is before placement agent fees and other expenses.

TCGX leads the group, which includes new and existing investors: abrdn World Healthcare Fund, ADAR1 Capital Management, Balyasny Asset Management, Cormorant Asset Management, Frazier Life Sciences, RA Capital Management, RTW Investments, Sirenia Capital Management, Wellington Management and Woodline Partners.

Zai Lab shares closed at $22.04 on Thursday, down about 9% from the prior session, according to market data. The company's market value was $2.5 billion.

Money for zoci

Zai Lab said it intends to use the net proceeds primarily to support global development of zocilurtatug pelitecan, or zoci, an antibody-drug conjugate aimed at DLL3. The 8-K also lists pipeline funding, working capital and general corporate purposes.

A corporate presentation furnished with the filing, published Friday, shows zoci plus atezolizumab produced an 81.8% confirmed response rate at 1.6 mg/kg in first-line small cell lung cancer. The deck lists a potential biologics license application for zoci in the second half of 2027 and three pivotal trials by year-end 2026.

It also shows $718 million in cash as of June 30, 2026, and second-quarter revenue of $106 million.

Closing and resale registration

The placement is expected to close on or about October 27. Zai Lab has agreed to file a registration statement covering resale of the ADSs within 15 days of closing, subject to certain allowable delays.

The company, which in its 10-K lists marketed products including ZEJULA, VYVGART and NUZYRA, has said the deal could fail to close on the anticipated terms, or at all.

Zai Lab's deck points to the 2027 filing window for zoci as the next major milestone, with the placement due to close October 27.

Sources